Given the overwhelming evidence that NF-κB plays a crucial role in tumor resistance to radiotherapy and chemotherapy, targeting NF-κB inhibition at the molecular level is being actively pursued as a novel adjuvant strategy in cancer treatment [357,358]. The gene discussed is NFKB1; the disease is cancer.